News 24 Jun. 2021
Curtis successfully defends foreign states' procedural privileges in the UK Supreme Court
News 23 Jun. 2021
Ibrahim Elsadig joins Curtis as Partner in Dubai
Client Alert 24 Feb. 2022
EU, UK, Japan and Australia Impose Sanctions on Russia
News 09 Aug. 2021
Curtis, Mallet-Prevost, Colt & Mosle enters into association with Chevalier Law in Singapore.
News 06 May. 2022
Curtis Advises Terna Group on the Sale of its Latin America Power Transmission Assets to CDPQ
Publications 05 May. 2022
Marie-Claire Argac, Simon Batifort, and Cyprien Mathié share highlights from “Affaires d’Etats: Practical Considerations When Defending States in International Arbitration” on Kluwer Arbitration Blog
Event 26 Apr. 2022
Claudia Frutos-Peterson Speaks at CAI Costa Rica’s 13th Congress of International Arbitration
News 21 Apr. 2022
SCOTUS Upholds U.S. Colonialism under the U.S. Constitution
Client Alert 23 Mar. 2022
The Dubai International Arbitration Centre (DIAC) has launched the DIAC Arbitration Rules 2022
Event 22 Nov. 2021
Partner Antonia Birt spoke at ADGMAC and AIAC Webinar Series: Webinar 5 - Disputes in Fintech and Complex Technology in MESEA
News 16 May. 2022
Curtis Files SCOTUS Amicus Brief for Ohio Justice & Policy Center in Prisoners’ Rights Case
News 10 May. 2022
Juan Perla’s Argument in D.C. Circuit Featured on Audio Arguendo Podcast
Client Alert 21 Apr. 2022
New Laws Targeting Assets of Russian Oligarchs: The U.S. Announces Task Force KleptoCapture and the Kleptocracy Asset Recovery Rewards Program
Client Alert 19 Apr. 2022
U.S. President Biden Expands Export Controls Imposed on Russia and Belarus
Client Alert 24 Jun. 2021
Update on Virtual Notarization (Executive Order 202.7) During the COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Update on Virtual Witnessing (New York Executive Order 202.14) During The COVID-19 (Coronavirus) Pandemic (Updated: June 24, 2021) — U.S. Insight
Companies operating in the pharmaceutical and related sectors such as healthcare must grapple with cutting-edge scientific development as well as shifting regulatory regimes, which complicate corporate mergers and acquisitions, managing intellectual property portfolios and patents, and litigating disputes. The ethical dimension makes it imperative to have the right legal advice.
Curtis provides a wide range of legal services to clients in the pharmaceutical sector. Our pharmaceutical attorneys advise manufacturers, funds and institutions on transactions and disputes involving branded and generic pharmaceuticals, biotechnology equipment, clinical systems, nanotechnology, medical software and prescription drugs, drug delivery and drug packaging.
We have advised on a diverse range of mergers and acquisitions and other transactions.
The wider Curtis team includes experts in the field of healthcare compliance, as well as former medical doctors and lawyers with experience in pharmaceutical patent and regulatory (Hatch-Waxman) litigation in the U.S.
This has enabled Curtis to develop a range of experience in the pharmaceutical sector, ranging from healthcare issues to compliance and specialist intellectual property. Our healthcare attorneys have also advised on the development and financing of healthcare infrastructure projects such as hospitals in many countries, by way of PPI as well as traditional project finance and Islamic finance.
Intellectual Property Litigation
Commercial Disputes - Litigation
Legal 500 USA, 2019
Legal 500: USA M&A(Middle-Market) 2017
Legal 500 USA 2019